SCHEMBL3976016

SCHEMBL3976016

NNC(=O)c1occc1-c1ccccc1Oc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ADRA2C P18825 1/20 0.42
CTNNB1 P35222 1/20 0.41
SLC9A1 P19634 1/20 0.41
FFAR4 Q5NUL3 2/20 0.40
ALDH1A1 P00352 4/20 0.40
MAPK1 P28482 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
HPGD P15428 2/20 0.40
TSHR P16473 2/20 0.40
ESR1 P03372 1/20 0.40
POLB P06746 1/20 0.40
ALOX15 P16050 1/20 0.40
APEX1 P27695 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27605287 0.84 SMN1; SMN2 (0.45) MEN1KMT2ASMN1; SMN2MAPTNPC1
SCHEMBL3976519 0.82 NPC1 (0.44) MEN1KMT2ASMN1; SMN2MAPTNPC1
SCHEMBL3981591 0.82 SGMS2 (0.49) MEN1KMT2ASMN1; SMN2MAPTNPC1
SCHEMBL3976435 0.80 IRAK4 (0.42) MEN1KMT2ASMN1; SMN2MAPTNPC1
SCHEMBL3977608 0.80 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3978096 0.79 MEN1 (0.50) MEN1KMT2ASMN1; SMN2MAPTNPC1
SCHEMBL3976785 0.79 GAA (0.43) MEN1KMT2ASMN1; SMN2MAPTNPC1
SCHEMBL3982443 0.79 NPSR1 (0.43) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL3977209 0.77 HSD17B10 (0.34) MEN1KMT2ASMN1; SMN2MAPTNPC1
SCHEMBL3977123 0.77 MAPT (0.39) MEN1KMT2ASMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 MEN1 1481/4885KMT2A 3459/4885SMN1; SMN2 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.